Table 3

Microbiology and antimicrobial therapy by treatment group

Standard care n=138Rapid test-and-treat n=134Placebo n=137Lactobacillus reuteri probiotic n=135
Participants with treatable bacterial pathogens (Campylobacter, Shigella, enterotoxigenic Escherichia coli, enteropathogenic E. coli); n (%)82 (59.4)84 (62.7)84 (61.3)82 (60.7)
Participants with Cryptosporidium; n (%)4 (2.9)8 (6.0)5 (3.6)7 (5.2)
Participants documented as treated with cefotaxime; n (%)21 (15.6)21 (16.0)21 (15.7)21 (15.9)
 Missing3333
Participants documented as treated with amoxicillin/clavulanic acid; n (%)7 (5.3)7 (5.3)9 (6.8)5 (3.8)
 Missing6354
Participants documented as treated with nalidixic acid; n (%)8 (6.0)8 (6.1)11 (8.2)5 (3.8)
 Missing4334
Participants documented as treated with gentamicin; n (%)28 (20.7)30 (22.7)31 (23.0)27 (20.5)
 Missing3223
Participants documented as treated with azithromycin; n (%)069 (51.5)36 (26.3)33 (24.4)
Participants documented as treated with nitazoxanide; n (%)05 (3.7)2 (1.5)3 (2.2)